Spectrum Dynamics Medical has gained US Food and Drug Administration (FDA) clearance for the Veritas.AI Noise Reduction platform, setting the company up to advance the performance capabilities of its VERITON-CT SPECT/CT nuclear imaging system.

Veritas.AI uses a deep learning convolutional neural network (CNN) that is designed to reduce image noise while preserving spatial resolution and quantitative accuracy. According to Spectrum Dynamics, the platform has been clinically validated for applications and tracers including bone imaging and Lu-177 theranostics, a treatment for prostate cancer patients, and will reduce VERITON-CT scan time by up to 50%.

The platform is also expected to improve VERITON-CT’s image quality in low-count and high-noise conditions within what Spectrum describes as some of nuclear medicines’ “most demanding” imaging scenarios.